Newbury Pharmaceuticals expands its portfolio with four new products
Newbury Pharmaceuticals is strengthening its distribution partnership with an existing collaborator by adding four already registered products to its portfolio. The company plans to commercialize these products by the end of 2025, acting as the local representative responsible for all commercial activities.
Expanding the portfolio with additional products from this partnership has been an ambition for Newbury. With regulatory approvals already in place, the company is set to launch the new products by year-end.
“This expansion reinforces our commitment to being the preferred partner for companies without a presence in the Nordics. The addition of these four products further validates our business model and underscores the strength of our partnerships,” said Lars Minor, CEO of Newbury Pharmaceuticals.